Abstract
SARS-CoV-2 infection rates displayed striking temporal and spatial variation during the emergence of new variants globally and within the United States. While spatiotemporal “waves” of infection have been observed, quantitative assessments of their spread remain limited. Here, we estimate and compare the speed and spatial extent of the first two major infection waves in the United States, illustrating these dynamics through detailed visualizations. Our findings reveal that the origins of these waves coincide with large gatherings and the relaxation of masking mandates. Notably, the second wave spread more rapidly than the first, driven by multiple, non-contiguous origins of infection. This highlights the role of regional heterogeneity in epidemic dynamics and underscores the importance of localized public health measures in mitigating ongoing outbreaks.
Author Summary Over the pandemic of SARS-CoV-2, efforts to identify and visualize the disease progression were made. However, quantitative visualization of the infections spreading are limited until today. Here we developed tools to visualize the spatial and temporal spreading of SARS-CoV-2 first two waves of infections over the Contiguous United States. We generated novels figures and movies that captures the dynamics of spreading and developed a new mapping of incidence of SARS-CoV-2 that goes below county-level. These outputs can help public health understanding and control efforts of the disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is supported by Cooperative Agreement NU38OT000297 from the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE), SHEPheRD Contract 200-2016-91779 from the CDC, and the CDC Broad Agency Announcement Contract 75D30122C14697. This work does not necessarily represent the views of the CDC or CSTE.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.